70.07
price up icon0.56%   0.39
after-market After Hours: 70.06 -0.010 -0.01%
loading
Astrazeneca PLC stock is traded at $70.07, with a volume of 4.25M. It is up +0.56% in the last 24 hours and down -0.48% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$69.68
Open:
$70.09
24h Volume:
4.25M
Relative Volume:
0.84
Market Cap:
$228.90B
Revenue:
$54.98B
Net Income/Loss:
$7.77B
P/E Ratio:
28.14
EPS:
2.49
Net Cash Flow:
$9.14B
1W Performance:
-0.98%
1M Performance:
-0.48%
6M Performance:
+5.34%
1Y Performance:
-11.39%
1-Day Range:
Value
$69.66
$70.37
1-Week Range:
Value
$69.65
$71.14
52-Week Range:
Value
$61.24
$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name
Name
Astrazeneca PLC
Name
Phone
44 20 3749 5000
Name
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Employee
61,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
70.07 228.90B 54.98B 7.77B 9.14B 2.49

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Initiated Exane BNP Paribas Outperform
Feb-13-25 Upgrade UBS Neutral → Buy
Feb-12-25 Initiated Morgan Stanley Overweight
Nov-20-24 Upgrade UBS Sell → Neutral
Nov-06-24 Upgrade Deutsche Bank Sell → Hold
Sep-13-24 Downgrade Deutsche Bank Hold → Sell
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca PLC Stock (AZN) Latest News

pulisher
Jun 18, 2025

AstraZeneca (NASDAQ:AZN) PLC Stock Sees Institutional Growth on Nasdaq Composite - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

AstraZeneca and GSK fall after Trump renews pharma tariff threat - Proactive Investors

Jun 18, 2025
pulisher
Jun 18, 2025

FTSE 100 Live: Stocks drop and oil spikes as Iran 'will not surrender', AstraZeneca falls on tariff threat - Proactive Investors

Jun 18, 2025
pulisher
Jun 18, 2025

FTSE 100 Live: Stocks drop into the red, AstraZeneca and GSK fall on Trump tariff threat - Proactive Investors

Jun 18, 2025
pulisher
Jun 18, 2025

AstraZeneca, GSK shares down after Trump threatens drug import tariffs By Investing.com - Investing.com Nigeria

Jun 18, 2025
pulisher
Jun 18, 2025

FTSE 100 Live: Stocks edge higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors

Jun 18, 2025
pulisher
Jun 18, 2025

FTSE 100 Live: Stocks open higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors

Jun 18, 2025
pulisher
Jun 17, 2025

Astrazeneca makes $5.3B drug R&D pact with CSPC - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

AstraZeneca (AZN) Faces Potential Changes in Drug Advertising Ru - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN - ACCESS Newswire

Jun 16, 2025
pulisher
Jun 16, 2025

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance

Jun 16, 2025
pulisher
Jun 15, 2025

AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

Jun 14, 2025
pulisher
Jun 13, 2025

Sector Update: Health Care Stocks Slide Late Afternoon - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca Inks Up To $5.3B AI Drug Deal With Chinese Firm - Law360

Jun 13, 2025
pulisher
Jun 13, 2025

FIVE AT FIVE: FTSE 100 unsettled by Israel strike; AstraZeneca strikes $3.6bn Chinese AI deal - Proactive financial news

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca and CSPC partner on AI drug research By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca and CSPC partner on AI drug research - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal - Pharmaceutical Technology

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca, CSPC Pharmaceuticals Enter Research Agreement - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca signs research agreement with China's CSPC (AZN) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - BioPharma Dive

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance - insights.citeline.com

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 BillionAstraZeneca (NASDAQ:AZN) - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca, Chinese bio firm sign $5.2B drug deal - breakingthenews.net

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech - Financial Times

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca Signs Nearly $5.3 Bln AI-enabled Research Deal With China's CSPC Pharma - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca (AZN) Enters Collaboration with CSPC for Novel Thera - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca: R&D agreement with CSPC Pharmaceuticals Group - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca bets big on AI and China with $3.6bn CSPC collaboration - Proactive financial news

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca Enters Strategic Collaboration with CSPC Pharmaceuticals Group Limited - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca, CSPC Ink Strategic Research Collaboration for AI-Driven Drug Discovery - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies - TradingView

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca partners with CSPC in deal worth up to $5.33 billion - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca forms $5.3 billion AI drug discovery deal with CSPC - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca signs AI research deal with China's CSPC for chronic diseases - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC - Yahoo Finance

Jun 13, 2025
pulisher
Jun 13, 2025

Astrazeneca Enters Collaboration Worth Up To $5.22 Bln With CSPC Pharmaceuticals - marketscreener.com

Jun 13, 2025
pulisher
Jun 12, 2025

Top Stock Reports for Microsoft, AstraZeneca & BlackRock - Yahoo Finance

Jun 12, 2025
pulisher
Jun 12, 2025

Chancery Tags AstraZeneca Unit For $180M 'Expectation' Loss - Law360

Jun 12, 2025
pulisher
Jun 12, 2025

Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes - Proactive financial news

Jun 12, 2025
pulisher
Jun 12, 2025

AstraZeneca CFO Donates Shares to Charity - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

AstraZeneca CFO donates shares to charity - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

AstraZeneca CFO donates shares to charity By Investing.com - Investing.com UK

Jun 12, 2025
pulisher
Jun 12, 2025

REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

AstraZeneca (AZN): Vaccine Advisory Panel Reshuffled, Impact on Pharma Stocks | AZN Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

UBS bullish on AstraZeneca’s baxdrostat, cautious on AVANZAR By Investing.com - Investing.com Nigeria

Jun 12, 2025
pulisher
Jun 12, 2025

At a bargain-basement valuation now, is AstraZeneca’s share price impossible for me to ignore? - Yahoo

Jun 12, 2025
pulisher
Jun 11, 2025

AstraZeneca (AZN) Watches CDC Vaccine Policy Developments | AZN Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

AstraZeneca Unit Owes $180 Million-Plus in Syntimmune Case (1) - Bloomberg Law News

Jun 11, 2025
pulisher
Jun 11, 2025

AstraZeneca, Lilly & J&J: Strategic Moves Powering SGLT‐2 - openPR.com

Jun 11, 2025

Astrazeneca PLC Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
Cap:     |  Volume (24h):